Skip to main content
Erschienen in: Neurocritical Care 3/2009

01.12.2009 | Original Article

Selective Immune Adsorption Treatment of Severe Guillain Barré Syndrome in the Intensive Care Unit

verfasst von: N. Galldiks, C. Dohmen, M. Neveling, G. R. Fink, W. F. Haupt

Erschienen in: Neurocritical Care | Ausgabe 3/2009

Einloggen, um Zugang zu erhalten

Abstract

Background

The effectiveness of plasma exchange and intravenous application of immunoglobulins (IVIG) for the treatment of the Guillain Barré syndrome (GBS) has been demonstrated in large collectives. In contrast, there are only a few investigations in GBS patients with severe symptoms admitted to the intensive care unit (ICU) and treated with selective immune adsorption (SIA). We compared the efficacy and safety of SIA only versus SIA followed by IVIG in patients with severe GBS.

Methods

Patients with severe GBS admitted to the ICU were treated with SIA only or in combination with IVIG. Severity of symptoms was assessed using Hughes grades and severe GBS was defined as ≥3. Data were acquired retrospectively for the last 10 years (1998–2008).

Results

Data from 30 GBS patients (age 53 ± 16 years) with severe symptoms (Hughes grade 5: 30% [n = 9], grade 4: 57% [n = 17], grade 3: 13% [n = 4]) were analyzed. The mean Hughes grade at admission was 4.2 ± 0.7. Ten patients were treated by SIA only, 20 patients were treated sequentially with SIA followed by IVIG (30 g/d) over 3 days. The number of SIA sessions was 3.2 ± 0.8. Improvement of Hughes grade 4.2 ± 0.7 to 3.4 ± 0.9 (P < 0.001) occurred within 14.6 ± 15.5 days. Treatment with SIA only was as effective as the sequential therapy with IVIG. The Hughes grade decreased significantly in the group of patients where SIA was performed only (P = 0.008) and in the sequential treatment group (P < 0.001), respectively. In one patient SIA had to be terminated after one session due to ICU complications. Other severe side effects were not observed.

Conclusions

In severely affected GBS patients admitted to ICU treatment with SIA seems to be safe and effective. In comparison to treatment with SIA only, sequential therapy with IVIG was not more effective.
Literatur
2.
Zurück zum Zitat Arasaki K, Kusunoki S, Kudo N, Kanazawa I. Acute conduction block in vitro following exposure to antiganglioside sera. Muscle Nerve. 1993;16:587–93.CrossRefPubMed Arasaki K, Kusunoki S, Kudo N, Kanazawa I. Acute conduction block in vitro following exposure to antiganglioside sera. Muscle Nerve. 1993;16:587–93.CrossRefPubMed
3.
Zurück zum Zitat Efficiency of plasma exchange in Guillain-Barre syndrome: role of replacement fluids. French Cooperative Group on Plasma Exchange in Guillain-Barre syndrome. Ann Neurol. 1987;22:753–61. Efficiency of plasma exchange in Guillain-Barre syndrome: role of replacement fluids. French Cooperative Group on Plasma Exchange in Guillain-Barre syndrome. Ann Neurol. 1987;22:753–61.
4.
Zurück zum Zitat Plasmapheresis and acute Guillain-Barre syndrome. The Guillain-Barre syndrome Study Group. Neurology. 1985;35:1096–104. Plasmapheresis and acute Guillain-Barre syndrome. The Guillain-Barre syndrome Study Group. Neurology. 1985;35:1096–104.
5.
Zurück zum Zitat Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barre syndrome. Plasma Exchange/Sandoglobulin Guillain-Barre Syndrome Trial Group. Lancet. 1997;349:225–30. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barre syndrome. Plasma Exchange/Sandoglobulin Guillain-Barre Syndrome Trial Group. Lancet. 1997;349:225–30.
6.
Zurück zum Zitat Haupt WF, Rosenow F, van der Ven C, Borberg H, Pawlik G. Sequential treatment of Guillain-Barre syndrome with extracorporeal elimination and intravenous immunoglobulin. J Neurol Sci. 1996;137:145–9.CrossRefPubMed Haupt WF, Rosenow F, van der Ven C, Borberg H, Pawlik G. Sequential treatment of Guillain-Barre syndrome with extracorporeal elimination and intravenous immunoglobulin. J Neurol Sci. 1996;137:145–9.CrossRefPubMed
7.
Zurück zum Zitat Diener HC, Haupt WF, Kloss TM, et al. A preliminary, randomized, multicenter study comparing intravenous immunoglobulin, plasma exchange, and immune adsorption in Guillain-Barre syndrome. Eur Neurol. 2001;46:107–9.CrossRefPubMed Diener HC, Haupt WF, Kloss TM, et al. A preliminary, randomized, multicenter study comparing intravenous immunoglobulin, plasma exchange, and immune adsorption in Guillain-Barre syndrome. Eur Neurol. 2001;46:107–9.CrossRefPubMed
8.
Zurück zum Zitat Okamiya S, Ogino M, Ogino Y, et al. Tryptophan-immobilized column-based immunoadsorption as the choice method for plasmapheresis in Guillain-Barre syndrome. Ther Apher Dial. 2004;8:248–53.CrossRefPubMed Okamiya S, Ogino M, Ogino Y, et al. Tryptophan-immobilized column-based immunoadsorption as the choice method for plasmapheresis in Guillain-Barre syndrome. Ther Apher Dial. 2004;8:248–53.CrossRefPubMed
9.
Zurück zum Zitat Seta T, Nagayama H, Katsura K, et al. Factors influencing outcome in Guillain-Barre syndrome: comparison of plasma adsorption against other treatments. Clin Neurol Neurosurg. 2005;107:491–6.CrossRefPubMed Seta T, Nagayama H, Katsura K, et al. Factors influencing outcome in Guillain-Barre syndrome: comparison of plasma adsorption against other treatments. Clin Neurol Neurosurg. 2005;107:491–6.CrossRefPubMed
10.
Zurück zum Zitat Pencz A, Garnier E. Immunoadsorption in the treatment of Guillain-Barre type polyradiculitis. Nervenarzt. 1990;61:372–5.PubMed Pencz A, Garnier E. Immunoadsorption in the treatment of Guillain-Barre type polyradiculitis. Nervenarzt. 1990;61:372–5.PubMed
11.
Zurück zum Zitat Jimenez C, Rosenow F, Grieb P, Haupt WF, Borberg H. Adsorption therapy with tryptophan-conjugated polyvinyl alcohol gels in 10 patients with acute Guillain-Barre syndrome. Transfus Sci. 1993;14:9–11.CrossRefPubMed Jimenez C, Rosenow F, Grieb P, Haupt WF, Borberg H. Adsorption therapy with tryptophan-conjugated polyvinyl alcohol gels in 10 patients with acute Guillain-Barre syndrome. Transfus Sci. 1993;14:9–11.CrossRefPubMed
12.
Zurück zum Zitat Shibuya N, Sato T, Osame M, Takegami T, Doi S, Kawanami S. Immunoadsorption therapy for myasthenia gravis. J Neurol Neurosurg Psychiatry. 1994;57:578–81.CrossRefPubMed Shibuya N, Sato T, Osame M, Takegami T, Doi S, Kawanami S. Immunoadsorption therapy for myasthenia gravis. J Neurol Neurosurg Psychiatry. 1994;57:578–81.CrossRefPubMed
13.
Zurück zum Zitat Grob D, Simpson D, Mitsumoto H, et al. Treatment of myasthenia gravis by immunoadsorption of plasma. Neurology. 1995;45:338–44.PubMed Grob D, Simpson D, Mitsumoto H, et al. Treatment of myasthenia gravis by immunoadsorption of plasma. Neurology. 1995;45:338–44.PubMed
14.
Zurück zum Zitat Hughes RA, Newsom-Davis JM, Perkin GD, Pierce JM. Controlled trial prednisolone in acute polyneuropathy. Lancet. 1978;2:750–3.CrossRefPubMed Hughes RA, Newsom-Davis JM, Perkin GD, Pierce JM. Controlled trial prednisolone in acute polyneuropathy. Lancet. 1978;2:750–3.CrossRefPubMed
15.
Zurück zum Zitat van der Meche FG, Schmitz PI. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barre syndrome. Dutch Guillain-Barre Study Group. N Engl J Med. 1992;326:1123–9.PubMed van der Meche FG, Schmitz PI. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barre syndrome. Dutch Guillain-Barre Study Group. N Engl J Med. 1992;326:1123–9.PubMed
16.
Zurück zum Zitat Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barre syndrome. Ann Neurol. 1990;27(Suppl):S21–4.CrossRefPubMed Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barre syndrome. Ann Neurol. 1990;27(Suppl):S21–4.CrossRefPubMed
17.
Zurück zum Zitat Hughes RA, Wijdicks EF, Barohn R, et al. Practice parameter: immunotherapy for Guillain-Barre syndrome: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2003;61:736–40.PubMed Hughes RA, Wijdicks EF, Barohn R, et al. Practice parameter: immunotherapy for Guillain-Barre syndrome: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2003;61:736–40.PubMed
Metadaten
Titel
Selective Immune Adsorption Treatment of Severe Guillain Barré Syndrome in the Intensive Care Unit
verfasst von
N. Galldiks
C. Dohmen
M. Neveling
G. R. Fink
W. F. Haupt
Publikationsdatum
01.12.2009
Verlag
Humana Press Inc
Erschienen in
Neurocritical Care / Ausgabe 3/2009
Print ISSN: 1541-6933
Elektronische ISSN: 1556-0961
DOI
https://doi.org/10.1007/s12028-009-9252-6

Weitere Artikel der Ausgabe 3/2009

Neurocritical Care 3/2009 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Schützt Olivenöl vor dem Tod durch Demenz?

10.05.2024 Morbus Alzheimer Nachrichten

Konsumieren Menschen täglich 7 Gramm Olivenöl, ist ihr Risiko, an einer Demenz zu sterben, um mehr als ein Vierten reduziert – und dies weitgehend unabhängig von ihrer sonstigen Ernährung. Dafür sprechen Auswertungen zweier großer US-Studien.

Bluttest erkennt Parkinson schon zehn Jahre vor der Diagnose

10.05.2024 Parkinson-Krankheit Nachrichten

Ein Bluttest kann abnorm aggregiertes Alpha-Synuclein bei einigen Menschen schon zehn Jahre vor Beginn der motorischen Parkinsonsymptome nachweisen. Mit einem solchen Test lassen sich möglicherweise Prodromalstadien erfassen und die Betroffenen früher behandeln.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Wartezeit nicht kürzer, aber Arbeit flexibler

Psychotherapie Medizin aktuell

Fünf Jahren nach der Neugestaltung der Psychotherapie-Richtlinie wurden jetzt die Effekte der vorgenommenen Änderungen ausgewertet. Das Hauptziel der Novellierung war eine kürzere Wartezeit auf Therapieplätze. Dieses Ziel wurde nicht erreicht, es gab jedoch positive Auswirkungen auf andere Bereiche.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.